Skip to main content
Top
Published in: Pathology & Oncology Research 2/2020

01-04-2020 | osteosarcoma | Original Article

Identification of Pathogenic Genes and Transcription Factors in Osteosarcoma

Authors: Chenggang Yang, Di Huang, Cui Ma, Jing Ren, Lina Fu, Cheng Cheng, Bangling Li, Xiaofeng Shi

Published in: Pathology & Oncology Research | Issue 2/2020

Login to get access

Abstract

Osteosarcoma (OS) is an aggressive malignant tumor of the bones. Our study intended to identify and analyze potential pathogenic genes and upstream regulators for OS. We performed an integrated analysis to identify candidate pathogenic genes of OS by using three Gene Expression Omnibus (GEO) databases (GSE66673, GSE49003 and GSE37552). GO and KEGG enrichment analysis were utilized to predict the functional annotation and potential pathways of differentially expressed genes (DEGs). The OS-specific transcriptional regulatory network was established to study the crucial transcriptional factors (TFs) which target the DEGs in OS. From the three GEO datasets, we identified 759 DEGs between metastasis OS samples and non-metastasis OS samples. After GO and KEGG analysis, ‘cell adhesion’ (FDR = 1.27E-08), ‘protein binding’ (FDR = 1.13E-22), ‘cytoplasm’ (FDR = 5.63E-32) and ‘osteoclast differentiation’ (FDR = 0.000992221) were significantly enriched pathways for DEGs. HSP90AA1 exhibited a highest degree (degree = 32) and was enriched in ‘pathways in cancer’ and ‘signal transduction’. BMP6, regulated by Pax-6, was enriched in the ‘TGF-beta signaling pathway’. We indicated that BMP6 may be downregulated by Pax-6 in the non-metastasis OS samples. The up-regulated HSP90AA1 and down-regulated BMP6 and ‘pathways in cancer’ and ‘signal transduction’ were deduced to be involved in the pathogenesis of OS. The identified biomarkers and biological process in OS may provide foundation for further study.
Literature
1.
go back to reference Zhou W, Hao M, Du X, Chen K, Wang G, Yang J (2014) Advances in targeted therapy for osteosarcoma. Discov Med 17(96):301–307PubMed Zhou W, Hao M, Du X, Chen K, Wang G, Yang J (2014) Advances in targeted therapy for osteosarcoma. Discov Med 17(96):301–307PubMed
2.
go back to reference Bernardini, G., Geminiani, M., Gambassi, S., Orlandini, M., Petricci, E., & Marzocchi, B., et al. (2017). Novel smoothened antagonists as anti-neoplastic agents for the treatment of osteosarcoma. J Cell Physiol Bernardini, G., Geminiani, M., Gambassi, S., Orlandini, M., Petricci, E., & Marzocchi, B., et al. (2017). Novel smoothened antagonists as anti-neoplastic agents for the treatment of osteosarcoma. J Cell Physiol
3.
go back to reference Yan H, Zhang B, Fang C, Chen L (2018) Mir-340 alleviates chemoresistance of osteosarcoma cells by targeting zeb1. Anti-Cancer Drugs:1 Yan H, Zhang B, Fang C, Chen L (2018) Mir-340 alleviates chemoresistance of osteosarcoma cells by targeting zeb1. Anti-Cancer Drugs:1
4.
go back to reference Pang Y, Zhao J, Fowdur M, Liu Y, Wu H, He M (2018) To explore the mechanism of the grm4 gene in osteosarcoma by rna sequencing and bioinformatics approach. Med Sci Monit Basic Res 24:16–25PubMedPubMedCentral Pang Y, Zhao J, Fowdur M, Liu Y, Wu H, He M (2018) To explore the mechanism of the grm4 gene in osteosarcoma by rna sequencing and bioinformatics approach. Med Sci Monit Basic Res 24:16–25PubMedPubMedCentral
5.
go back to reference Mitchell PJ, Tjian R (1989) Transcriptional regulation in mammalian cells by sequence-specific dna binding proteins. Science 245(4916):371–378PubMed Mitchell PJ, Tjian R (1989) Transcriptional regulation in mammalian cells by sequence-specific dna binding proteins. Science 245(4916):371–378PubMed
6.
go back to reference Zhu M, Liu CC, Cheng C (2013) Reactin: regulatory activity inference of transcription factors underlying human diseases with application to breast cancer. BMC Genomics 14(1):504PubMedPubMedCentral Zhu M, Liu CC, Cheng C (2013) Reactin: regulatory activity inference of transcription factors underlying human diseases with application to breast cancer. BMC Genomics 14(1):504PubMedPubMedCentral
7.
go back to reference Yang L, Feng S, Yang Y (2016) Identification of transcription factors (tfs) and targets involved in the cholangiocarcinoma (cca) by integrated analysis. Cancer Gene Ther 23(12):439–445PubMed Yang L, Feng S, Yang Y (2016) Identification of transcription factors (tfs) and targets involved in the cholangiocarcinoma (cca) by integrated analysis. Cancer Gene Ther 23(12):439–445PubMed
8.
go back to reference Diao C, Xi Y, Xiao T (2018) Identification and analysis of key genes in osteosarcoma using bioinformatics. Oncol Lett 15(3):2789–2794PubMed Diao C, Xi Y, Xiao T (2018) Identification and analysis of key genes in osteosarcoma using bioinformatics. Oncol Lett 15(3):2789–2794PubMed
9.
go back to reference Liu HY, Zhang CJ (2017) Identification of differentially expressed genes and their upstream regulators in colorectal cancer. Cancer Gene Ther 24:244–250PubMed Liu HY, Zhang CJ (2017) Identification of differentially expressed genes and their upstream regulators in colorectal cancer. Cancer Gene Ther 24:244–250PubMed
10.
go back to reference Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate-a practical and powerful approach to multiple testing. J R Stat Soc 57(1):289–300 Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate-a practical and powerful approach to multiple testing. J R Stat Soc 57(1):289–300
11.
go back to reference Li JJ, Wang BQ, Fei Q, Yang Y, Li D (2016) Identification of candidate genes in osteoporosis by integrated microarray analysis. Bone Joint Res 5(12):594–601PubMed Li JJ, Wang BQ, Fei Q, Yang Y, Li D (2016) Identification of candidate genes in osteoporosis by integrated microarray analysis. Bone Joint Res 5(12):594–601PubMed
12.
go back to reference Wang F, Wang R, Li Q, Qu X, Hao Y, Yang J, Zhao H, Wang Q, Li G, Zhang F, Zhang H, Zhou X, Peng X, Bian Y, Xiao W (2017) A transcriptome profile in hepatocellular carcinomas based on integrated analysis of microarray studies. Diagn Pathol 12(1):4PubMedPubMedCentral Wang F, Wang R, Li Q, Qu X, Hao Y, Yang J, Zhao H, Wang Q, Li G, Zhang F, Zhang H, Zhou X, Peng X, Bian Y, Xiao W (2017) A transcriptome profile in hepatocellular carcinomas based on integrated analysis of microarray studies. Diagn Pathol 12(1):4PubMedPubMedCentral
13.
go back to reference Lee YS, Kim JK, Ryu SW, Bae SJ, Kwon K, Noh YH, Kim SY (2015) Integrative meta-analysis of multiple gene expression profiles in acquired gemcitabine-resistant cancer cell lines to identify novel therapeutic biomarkers. Asian Pac J Cancer Prev 16(7):2793–2800PubMed Lee YS, Kim JK, Ryu SW, Bae SJ, Kwon K, Noh YH, Kim SY (2015) Integrative meta-analysis of multiple gene expression profiles in acquired gemcitabine-resistant cancer cell lines to identify novel therapeutic biomarkers. Asian Pac J Cancer Prev 16(7):2793–2800PubMed
14.
go back to reference Luetke A, Meyers PA, Lewis I, Juergens H (2014) Osteosarcoma treatment - where do we stand? A state of the art review. Cancer Treat Rev 40(4):523–532PubMed Luetke A, Meyers PA, Lewis I, Juergens H (2014) Osteosarcoma treatment - where do we stand? A state of the art review. Cancer Treat Rev 40(4):523–532PubMed
15.
go back to reference Guan D, Tian H (2017) Integrated network analysis to explore the key genes regulated by parathyroid hormone receptor 1 in osteosarcoma. World J Sugr Oncol 15(1):177 Guan D, Tian H (2017) Integrated network analysis to explore the key genes regulated by parathyroid hormone receptor 1 in osteosarcoma. World J Sugr Oncol 15(1):177
16.
go back to reference Taipale M, Jarosz DF, Lindquist S (2010) Hsp90 at the hub of protein homeostasis: emerging mechanistic insights. Nat Rev Mol Cell Biol 11(7):515–528PubMed Taipale M, Jarosz DF, Lindquist S (2010) Hsp90 at the hub of protein homeostasis: emerging mechanistic insights. Nat Rev Mol Cell Biol 11(7):515–528PubMed
17.
go back to reference Coskunpinar E, Akkaya N, Yildiz P, Oltulu YM, Aynaci E, Isbir T, Yaylim I (2014) The significance of hsp90aa1, hsp90ab1 and hsp90b1 gene polymorphisms in a turkish population with non-small cell lung cancer. Anticancer Res 34(2):753–757PubMed Coskunpinar E, Akkaya N, Yildiz P, Oltulu YM, Aynaci E, Isbir T, Yaylim I (2014) The significance of hsp90aa1, hsp90ab1 and hsp90b1 gene polymorphisms in a turkish population with non-small cell lung cancer. Anticancer Res 34(2):753–757PubMed
18.
go back to reference Chu SH, Liu YW, Zhang L, Liu B, Li L, Shi JZ, Li L (2013) Regulation of survival and chemoresistance by hsp90aa1 in ovarian cancer skov3 cells. Mol Biol Rep 40(1):1–6PubMed Chu SH, Liu YW, Zhang L, Liu B, Li L, Shi JZ, Li L (2013) Regulation of survival and chemoresistance by hsp90aa1 in ovarian cancer skov3 cells. Mol Biol Rep 40(1):1–6PubMed
19.
go back to reference Mckay, W., Boden, S., & Yoon, S. (2006). METHODS OF INDUCING THE EXPRESSION OF BONE MORPHOGENETIC PROTEINS (BMPs) AND TRANSFORMING GROWTH FACTOR-beta-PROTEINS (TGF-betas) IN CELLS. CA, EP1629106 Mckay, W., Boden, S., & Yoon, S. (2006). METHODS OF INDUCING THE EXPRESSION OF BONE MORPHOGENETIC PROTEINS (BMPs) AND TRANSFORMING GROWTH FACTOR-beta-PROTEINS (TGF-betas) IN CELLS. CA, EP1629106
20.
go back to reference Honda Y, Knutsen R, Strong DD, Sampath TK, Baylink DJ, Mohan S (1997) Osteogenic protein-1 stimulates mrna levels of bmp-6 and decreases mrna levels of bmp-2 and -4 in human osteosarcoma cells. Calcif Tissue Int 60(3):297–301PubMed Honda Y, Knutsen R, Strong DD, Sampath TK, Baylink DJ, Mohan S (1997) Osteogenic protein-1 stimulates mrna levels of bmp-6 and decreases mrna levels of bmp-2 and -4 in human osteosarcoma cells. Calcif Tissue Int 60(3):297–301PubMed
21.
go back to reference Shi, Y. J., & Pan, X. T. (2016). Bmp6 and bmp4 expression in patients with cancer-related anemia and its relationship with hepcidin and s-hjv. Genet Mol Res Gmr, 15(1) Shi, Y. J., & Pan, X. T. (2016). Bmp6 and bmp4 expression in patients with cancer-related anemia and its relationship with hepcidin and s-hjv. Genet Mol Res Gmr, 15(1)
22.
go back to reference Hu F, Zhang Y, Li M, Zhao L, Chen J, Yang S et al (2015) Bmp-6 inhibits the metastasis of mda-mb-231 breast cancer cells by regulating mmp-1 expression. Oncol Rep 35(3)PubMed Hu F, Zhang Y, Li M, Zhao L, Chen J, Yang S et al (2015) Bmp-6 inhibits the metastasis of mda-mb-231 breast cancer cells by regulating mmp-1 expression. Oncol Rep 35(3)PubMed
23.
go back to reference Liu G, Liu YJ, Lian WJ, Zhao ZW, Yi T, Zhou HY (2014) Reduced bmp6 expression by dna methylation contributes to emt and drug resistance in breast cancer cells. Oncol Rep 32(2):581–588PubMed Liu G, Liu YJ, Lian WJ, Zhao ZW, Yi T, Zhou HY (2014) Reduced bmp6 expression by dna methylation contributes to emt and drug resistance in breast cancer cells. Oncol Rep 32(2):581–588PubMed
24.
go back to reference Zong X, Yang H, Yu Y, Zou D, Ling Z, He X, Meng X (2011) Possible role of pax-6 in promoting breast cancer cell proliferation and tumorigenesis. BMB Rep 44(9):595–600PubMed Zong X, Yang H, Yu Y, Zou D, Ling Z, He X, Meng X (2011) Possible role of pax-6 in promoting breast cancer cell proliferation and tumorigenesis. BMB Rep 44(9):595–600PubMed
25.
go back to reference Shyr CR, Tsai MY, Yeh S, Kang HY, Chang YC, Wong PL et al (2010) Tumor suppressor pax6 functions as androgen receptor co-repressor to inhibit prostate cancer growth. Prostate 70(2):190–199PubMedPubMedCentral Shyr CR, Tsai MY, Yeh S, Kang HY, Chang YC, Wong PL et al (2010) Tumor suppressor pax6 functions as androgen receptor co-repressor to inhibit prostate cancer growth. Prostate 70(2):190–199PubMedPubMedCentral
Metadata
Title
Identification of Pathogenic Genes and Transcription Factors in Osteosarcoma
Authors
Chenggang Yang
Di Huang
Cui Ma
Jing Ren
Lina Fu
Cheng Cheng
Bangling Li
Xiaofeng Shi
Publication date
01-04-2020
Publisher
Springer Netherlands
Published in
Pathology & Oncology Research / Issue 2/2020
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-019-00645-w

Other articles of this Issue 2/2020

Pathology & Oncology Research 2/2020 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine